Article Text

PDF
Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience
  1. Paraskevi V Voulgari1,
  2. Aliki I Venetsanopoulou1,
  3. Efstratios K Epagelis1,
  4. Yannis Alamanos2,
  5. Ioanna Takalou1,
  6. Alexandros A Drosos1
  1. 1Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece
  2. 2Department of Hygiene and Epidemiology, Medical School, University of Ioannina, Ioannina, Greece
  1. Correspondence to:
    Professor A A Drosos
    Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece; adrosos{at}cc.uoi.gr

Statistics from Altmetric.com

Infliximab was shown to be effective and safe in controlled trials of psoriatic arthritis (PsA).1–4 In an open-label study, we reported a notable clinical benefit accompanied by clearing and healing of psoriatic skin lesions.5 Thus, we conducted this study to evaluate the efficacy and safety of infliximab in patients with active PsA and recalcitrant psoriasis in whom treatment with disease-modifying antirheumatic drugs had failed. Thirty two patients who had a negative purified protein derivative skin test and normal chest radiographs were included. All had an active disease, defined as ⩾6 tender or swollen joints count, psoriasis area and severity index (PASI) score ⩾10,6 and erythrocyte sedimentation rate ⩾28 mm Hg/h or C reactive protein concentration ⩾10 …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.